Cargando…

Correction to: PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse

Detalles Bibliográficos
Autores principales:	Zheng, Bingxin, Ren, Tingting, Huang, Yi, Sun, Kunkun, Wang, Shidong, Bao, Xing, Liu, Kuisheng, Guo, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846231/ https://www.ncbi.nlm.nih.gov/pubmed/29530070 http://dx.doi.org/10.1186/s13045-018-0580-x

Ejemplares similares

PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
por: Zheng, Bingxin, et al.
Publicado: (2018)

Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
por: Liu, Kuisheng, et al.
Publicado: (2017)

Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways
por: Ren, Tingting, et al.
Publicado: (2019)

Novel oncogene COPS3 interacts with Beclin1 and Raf-1 to regulate metastasis of osteosarcoma through autophagy
por: Zhang, Fan, et al.
Publicado: (2018)

BMPR2 promotes invasion and metastasis via the RhoA-ROCK-LIMK2 pathway in human osteosarcoma cells
por: Wang, Shidong, et al.
Publicado: (2017)

Knockdown of long non-coding RNA HOTAIR increases miR-454-3p by targeting Stat3 and Atg12 to inhibit chondrosarcoma growth
por: Bao, Xing, et al.
Publicado: (2017)

Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-125b is involved in the anti-migration/invasion effects of arsenic trioxide on human chondrosarcoma
por: Bao, Xing, et al.
Publicado: (2016)

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
por: Xie, Lu, et al.
Publicado: (2020)

Correction: Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3
por: Zhang, T., et al.
Publicado: (2019)

Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
por: Huang, Po-Lin, et al.
Publicado: (2023)

Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
por: Selby, Mark J., et al.
Publicado: (2016)

Correction: Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
Publicado: (2023)

Correction to: Pericardial effusion under nivolumab: case-reports and review of the literature
por: Saade, Anastasia, et al.
Publicado: (2019)

Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients
por: Wang, Jun, et al.
Publicado: (2020)

Correction to: MRI nomenclature for musculoskeletal infection
por: Alaia, Erin F., et al.
Publicado: (2022)

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2023)

Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)
por: Xie, Lu, et al.
Publicado: (2023)

Correction: CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
Publicado: (2021)

Correction to: Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment
por: Furune, Satoshi, et al.
Publicado: (2021)

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
por: Kjeldsen, Julie Westerlin, et al.
Publicado: (2022)

Correction to: Introduction to the minisymposium on small parts and musculoskeletal ultrasound
por: Epelman, Monica, et al.
Publicado: (2022)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Publicado: (2020)

Correction: Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages
Publicado: (2023)

Correction: CDKL3 promotes osteosarcoma progression by activating Akt/PKB
por: He, Aina, et al.
Publicado: (2022)

Correction: Cytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus
por: Zhao, Xing, et al.
Publicado: (2018)

Author Correction: Chlorin e6-associated photodynamic therapy enhances abscopal antitumor effects via inhibition of PD-1/PD-L1 immune checkpoint
por: Gurung, Pallavi, et al.
Publicado: (2023)

Correction To: Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
por: Gao, Yaohui, et al.
Publicado: (2021)

Correction Notice: A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
Publicado: (2021)

Correction to: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
por: Jiang, Huihui, et al.
Publicado: (2021)

Correction: Annexin A13 promotes tumor cell invasion in vitro and is associated with metastasis in human colorectal cancer
por: Jiang, Guozhong, et al.
Publicado: (2023)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Correction: PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice
Publicado: (2021)

Correction: Non-peptide compounds from Kronopolites svenhedini (Verhoeff) and their antitumor and iNOS inhibitory activities
por: Yuan, Yuan-Nan, et al.
Publicado: (2023)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
por: Liu, Xiaoqiang, et al.
Publicado: (2019)

Correction to: Recovery trajectories in common musculoskeletal complaints by diagnosis contra prognostic phenotypes
por: Aasdahl, Lene, et al.
Publicado: (2021)

Correction: Novel insights into the METTL3-METTL14 complex in musculoskeletal diseases
por: Xu, Yeqiu, et al.
Publicado: (2023)

Correction to: An International Multidisciplinary Delphi-Based Consensus on Heat Therapy in Musculoskeletal Pain
por: Lubrano, Ennio, et al.
Publicado: (2022)

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
por: Xie, Lu, et al.
Publicado: (2021)

Correction: Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor
por: Chung, Suyoun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qj8bp9pr8giivpsb42cgeap54r